携带抑制素α亚基shRNA的基因工程鼠伤寒沙门菌在癌症治疗中的治疗优势
本研究分析了抑制素α亚基(INHA)在正常与癌细胞组织中的表达,并构建携带靶向INHA的shRNA的减毒鼠伤寒沙门菌(S. typhimurium/sh-INHA)。在细胞模型和同系小鼠肿瘤模型中评估其治疗效果。结果显示结肠癌和黑色素瘤中INHA表达显著高于正常组织,S. typhimurium/sh-INHA相比未修饰菌或对照shRNA菌引起显著细胞毒性,并抑制小鼠结肠癌和黑色素瘤生长且具生存优势。提示肿瘤靶向S. typhimurium/sh-INHA或为新型癌症治疗选择。
要点
- INHA在结肠癌和黑色素瘤中表达显著高于正常组织。
- S. typhimurium/sh-INHA在细胞模型中引起显著细胞毒性。
- S. typhimurium/sh-INHA抑制小鼠结肠癌和黑色素瘤生长并具生存优势。
核心结论
- 肿瘤靶向的S. typhimurium/sh-INHA可能提供一种新的癌症治疗选择。
研究设计与样本
- 研究分析了人INHA在正常与癌细胞和组织中的表达,并构建携带sh-INHA的基因工程减毒鼠伤寒沙门菌。
- 采用细胞培养模型和同系小鼠肿瘤模型评估S. typhimurium/sh-INHA的癌症治疗效果。
主要发现
- INHA在结肠癌和黑色素瘤细胞及组织中的表达水平显著高于正常对应组织。
- 抑制INHA表达轻度降低癌细胞存活,并诱导caspase激活及抗凋亡蛋白Bcl-2和Bcl-xL表达下调。
- 基因工程S. typhimurium轻度干扰沙门菌侵入宿主结肠癌和黑色素瘤细胞,但S. typhimurium/sh-INHA相比未修饰菌或对照shRNA菌引起显著细胞毒性。
- S. typhimurium/sh-INHA处理小鼠显示结肠癌和黑色素瘤生长显著抑制,并具生存优势。
临床怎么用
- 目前仅为临床前研究,尚不能直接指导临床实践。
局限性
- 研究仅使用细胞培养模型和同系小鼠肿瘤模型,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In contrast to its well-known endocrine function, the role of inhibin in cancer development and therapeutic response is unclear. Salmonella, particularly less toxic attenuated Salmonella strains, are used to treat cancer in two ways. First, Salmonella accumulate around tumors, penetrate the cell barrier, and replicate inside the tumors. Second, Salmonella can act as a vehicle for delivering anticancer agents or proapoptotic genes to attack tumors. In this study, we aimed to develop a suitable cancer therapeutic strategy by genetically modifying attenuated Salmonella typhimurium to harbor short hairpin RNA (shRNA) expression plasmids targeting alpha subunit of inhibin (sh-INHA). METHODS: We analyzed the expression of human INHA in normal and cancer cells and tissues. We developed genetically engineered attenuated S. typhimurium harboring sh-INHA (S. typhimurium/sh-INHA) and assessed its cancer therapeutic effects by using cell culture models and syngeneic mouse tumor models. RESULTS: INHA expression levels were markedly higher in colon cancer and melanoma cells and tissues than in their normal counterparts. Suppression of INHA expression mildly reduced cancer cell survival and induced caspase activation and downregulation of anti-apoptotic Bcl-2 and Bcl-xL expressions. Although the genetically engineered S. typhimurium mildly interfered with the invasion of S. typhimurium into host colon cancer and melanoma cells, S. typhimurium/sh-INHA caused remarkable cytotoxicity in cancer compared with unmodified S. typhimurium or S. typhimurium expressing a control scrambled shRNA (S. typhimurium/sh-Cont). Salmonella typhimurium/sh-INHA-treated mice also showed a significantly inhibited growth of colon cancers and melanomas, with a survival advantage. CONCLUSION: Our results suggest that tumor-targeted therapy using S. typhimurium/sh-INHA may provide a novel cancer treatment option.
引用
- Yoon W, Yoo Y, Chae YS, et al. Therapeutic advantage of genetically engineered Salmonella typhimurium carrying short hairpin RNA against inhibin alpha subunit in cancer treatment. Ann Oncol. 2018. PMID: 30016386. doi:10.1093/annonc/mdy240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。